TrialBMC neurology2013

The ReSPonD trial--rivastigmine to stabilise gait in Parkinson's disease a phase II, randomised, double blind, placebo controlled trial to evaluate the effect of rivastigmine on gait in patients with Parkinson's disease who have fallen.

Emily J Henderson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.